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Abstract
Background: Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder with monogenic mutations
setting the stage for successful gene therapy treatment. We have completed a study that directly deals with the following
key issues that can be directly adapted to a gene therapy clinical trial using rAAV considering the following criteria: 1) A
regional vascular delivery approach that will protect the patient from widespread dissemination of virus; 2) an approach
to potentially facilitate safe passage of the virus for efficient skeletal muscle transduction; 3) the use of viral doses to
accommodate current limitations imposed by vector production methods; 4) and at the same time, achieve a clinically
meaningful outcome by transducing multiple muscles in the lower limb to prolong ambulation.
Methods: The capacity of AAV1, AAV6 or AAV8 to cross the vascular endothelial barrier carrying a micro-dystrophin
cDNA was compared under identical conditions with delivery through a catheter placed in the femoral artery of the mdx
mouse. Transduction efficiency was assessed by immuno-staining using an antibody (Manex1a) that recognizes the N-
terminus of micro-dystrophin. The degree of physiologic correction was assessed by measuring tetanic force and
protection from eccentric contraction in the extensor digitorum longus muscle (EDL). The vascular delivery paradigm
found successful in the mouse was carried to the non-human primate to test its potential translation to boys with DMD.
Results: Regional vascular delivery resulted in transduction by rAAV8.micro-dystrophin reaching 94.5 ± 0.9 (1 month),
91.3 ± 3.1 (2 months), and 89.6 ± 1.6% (3 months). rAAV6.micro-dystrophin treated animals demonstrated 87.7 ± 6.8
(1 month), 78.9 ± 7.4 (2 months), and 81.2 ± 6.2% (3 months) transduction. In striking contrast, rAAV1 demonstrated
very low transduction efficiency [0.9 ± 0.3 (1 month), 2.1 ± 0.8 (2 months), and 2.1 ± 0.7% (3 months)] by vascular
delivery. Micro-dystrophin delivered by rAAV8 and rAAV6 through the femoral artery significantly improved tetanic
force and protected against eccentric contraction. Mouse studies translated to the hindlimb of cynamologous macaques
using a similar vascular delivery paradigm. rAAV8 carrying eGFP in doses proportional to the mouse (5 × 1012 vg/kg in
mouse vs 2 × 1012 vg/kg in monkey) demonstrated widespread gene expression [medial gastrocnemius – 63.8 ± 4.9%,
lateral gastrocnemius – 66.0 ± 4.5%, EDL – 80.2 ± 3.1%, soleus – 86.4 ± 1.9%, TA – 72.2 ± 4.0%.
Conclusion: These studies demonstrate regional vascular gene delivery with AAV serotype(s) in mouse and non-human
primate at doses, pressures and volumes applicable for clinical trials in children with DMD.
Published: 24 September 2007
Journal of Translational Medicine 2007, 5:45 doi:10.1186/1479-5876-5-45
Received: 16 July 2007
Accepted: 24 September 2007
This article is available from: http://www.translational-medicine.com/content/5/1/45
© 2007 Rodino-Klapac et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
Journal of Translational Medicine 2007, 5:45 http://www.translational-medicine.com/content/5/1/45Background
Duchenne muscular dystrophy (DMD) is the most com-
mon, genetically inherited, progressive muscle disease of
childhood affecting 1 in 3,500 newborn males. [1] A lim-
ited treatment option can be offered through the use of
corticosteroids, prolonging ambulation in some but not
all patients. [2] Multiple treatment strategies are in evolu-
tion including some currently being tested in clinical tri-
als. These include exon skipping [3,4], mutation
suppression for premature stop codons [5,6], and phar-
macologic agents promoting muscle growth modulation.
[7,8] Promising findings are also emerging from experi-
mental gene replacement therapy in dystrophic mice [9-
12] and dogs. [4,13,14] In the clinic, lessons learned from
these studies are currently restricted to recombinant AAV
(rAAV) mediated gene delivery to single muscles by direct
injection. While this approach is important in laying the
foundation for future studies, clinically meaningful
results would best be attained through gene transfer
reaching widespread muscle targets in order to signifi-
cantly improve the quality of life for an individual patient.
Gene delivery via a vascular route offers this possibility,
dictating a direction to be followed in planning future
clinical trials.
In the mouse, AAV serotypes 6 and 8 have been shown to
be well-suited for systemic vascular delivery. Gregorevic et
al. illustrated widespread vascular delivery of the micro-
dystrophin cassette to skeletal muscle in the mdx mouse
[9,10], while Wang et al. demonstrated the potential for
rAAV8 vectors to achieve skeletal muscle transduction in
limb muscles remote from the delivery site. [15] These
prior studies are of interest to clinical trialists but do not
translate directly to the bedside. The very large viral load
required to achieve widespread AAV6 transduction using
tail vein delivery in the mdx mouse would challenge cur-
rent vector production methods, clearly limiting clinical
application. The AAV8 studies employed neonatal mice,
where vascular permeability factors differ from the more
mature vascular bed of the DMD patient. In addition,
AAV1 cannot be excluded from consideration because of
its established efficiency for skeletal muscle transduction
following direct injection [16,17] and its demonstrated
potential for robust dystrophin expression following vas-
cular delivery through the femoral artery of a specialized
exon skip cassette in the mdx model. [18] However, the
true potential for adapting AAV1 to a vascular delivery
clinical trial is unknown because the mouse studies
employed a large fluid volume, rapidly delivered through
the femoral artery, accompanied by rupture the capillary
endothelial bed and edema of the lower limb extremities.
While these observations in the mouse are important,
none of the studies meet the following criteria that can be
directly adapted to a clinical trial:
1) A regional vascular delivery approach that protects the
patient from widespread dissemination of virus; 2) per-
mits safe passage of the virus given more recent informa-
tion on the immunogenicity of AAV [19]; 3) uses viral
doses that will accommodate current limitations imposed
by vector production methods; and at the same time, 4)
achieves a clinically meaningful outcome (e.g., prolonged
ambulation by transducing multiple muscles in the limb).
The study presented here attempts to meet these criteria.
The first step toward achieving our goal was to test AAV1,
AAV6 and AAV8 under identical conditions, an experi-
ment not previously done, to establish which serotype is
most likely to be successful in a regional vascular delivery
clinical trial. Attempting to avoid the trap of translating
results directly from the mouse to the patient under the
assumption that such studies necessarily predict efficacy at
the bedside, we extended our observations to non-human
primates employing conditions that would closely simu-
late a clinical delivery model. The results of this stepwise
approach are presented here.
Methods
Animals and Treatments
All procedures were approved by the CCRI Institutional
Animal Care and Use Committee. Three to four week old
mdx mice and normal age-matched C57/BL10 were used
for vascular delivery and force generation studies of the
extensor digitorum longus (EDL) muscle. Two-year old
cynamologous macaques were pre-screened for binding
antibodies to AAV8 by ELISA and those that scored nega-
tive at a 1:50 serum dilution were included for isolated
limb perfusion studies. All non-human primates were
housed in pairs to promote socialization.
Isolated Limb Perfusion Studies in the Mouse
Mice were weighed and then anesthetized with a combi-
nation of ketamine and xylazine (100 mg/kg and 10 mg/
kg, respectively). The left groin was shaved to the mid-
thigh and treated with 95% ethanol and Povidine iodine
solution. The femoral bundle was visualized via a small
incision proximal to the mid-thigh and vessels were dis-
sected away from the femoral nerve. A 6-0 braided silk
tourniquet was placed around the limb under the vessel,
such that, when tightened, blood flow in and out of the
leg was prevented. Blood flow through the femoral artery
and vein was controlled by catheter placement in each
vessel using a customized heat pulled polypropylene 10
(PE-10) catheter placed into the vessels using an intro-
ducer hole with a 33-gauge needle. Prior to vector admin-
istration, the arterial catheter was flushed (pre-flush) with
100 µl sterile normal saline. Immediately prior to vector
administration all blood flow to the extremity was
impeded (isolated limb perfusion – ILP) by tightening the
ligature at the mid-thigh. The femoral vein catheter was
also occluded preventing vascular egress from the extrem-Page 2 of 11
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perfused through the femoral artery in 100 µl of sterile
Tris buffered saline administered at a rate of approxi-
mately 2 µl per second (over 60–80 seconds). After 10
minutes of maintained vascular occlusion, the femoral
venous catheter was opened and 100 ul of normal saline
was administered to the arterial catheter (again at about 2
µl per second) as a post-flush. Non-tissue bound vector
exited the extremity through the patent venous side. The
mid-thigh tourniquet was then released, the catheters
removed, and bleeding was controlled by direct pressure
to the vessels. The wound was flushed with sterile normal
saline and closed with a 6-0 proline suture.
For intramuscular injections, mice were anesthetized and
maintained on 1–4% Isoflurane (in Oxygen). Both hind
limbs were shaved and the tibialis anterior muscle was
injected with 3 × 1010 vg of rAAV1, 6, or 8.micro-dys-
trophin or normal saline (30 µl volume) using a 30 gauge
ultra-fine insulin syringe.
Isolated Limb Perfusion Studies in Macaques
Cynamologous macaques were sedated with intramuscu-
lar telazol (3–6 mg/kg), intubated and secured to a heated
procedure table at 37°C. General anesthesia was adminis-
tered with Isoflurane (in Oxygen) 1–4% during the proce-
dure. The left groin was shaved with extension to the mid
thigh, and prepped with 95% ethanol and Povidine
iodine solution. Working with a larger animal (2–3 Kg)
has advantages for catheter placement and more closely
simulates the leg of a child. A groin incision was made and
the femoral artery and vein were isolated. The femoral
artery was catheterized using a custom made, fluoroscopy
guided 3-0 f catheter that was advanced to the arterial
bifurcation at the level of the knee. Prior to vector admin-
istration a pre-vector flush was performed using a 2 ml
volume of saline. This was immediately followed by
occluding blood flow to the extremity using a standard
phlebotomy tourniquet placed above the exposed femo-
ral artery and vein. For these studies, only a single vector
construct, rAAV8.CMV.eGFP, was infused over 60 seconds
at a dose of 1013 vg (2 × 1012/kg) in 2 ml of Tris buffered
saline. The extremity remained isolated from the circula-
tion for 10 minutes before releasing the tourniquet. A
post-vector flush consisting of a volume of 2 ml was
infused simultaneous to the release of the thigh tourni-
quet. Hemostasis and wound closure were similar to the
mouse experiments.
Micro-dystrophin gene construction
The murine micro-dystrophin construct possessed the
(R4–R23/∆71–78) domains as previously described. [20]
The cDNA was codon optimized for rodents and synthe-
sized by GenScript Inc. It includes a consensus Kozak
sequence, an SV40 intron, and synthetic polyadenylation
site (53 bp). A truncated MCK (muscle creatine kinase)
promoter/enhancer was used to drive muscle specific gene
expression. The MCK micro-dystrophin expression cas-
sette was cloned between AAV2 ITRs using flanking Xba I
restriction enzyme sites in plasmid derived from pCMVβ
(Clontech). Msc I/Sma I restriction enzyme digestions
were used to confirm ITR integrity.
rAAV Vector production
rAAV vectors were produced by a modified cross-packag-
ing approach whereby the AAV type 2 vector genome can
be packaged into multiple AAV capsid serotypes. [21] Pro-
duction was accomplished using a standard 3 plasmid
DNA/CaPO4 precipitation method using HEK293 cells.
293 cells were maintained in DMEM supplemented with
10% fetal bovine serum (FBS) and penicillin and streptomy-
cin. The production plasmids were: (i) pAAV.MCK.micro-
dys, (ii) rep2-capX modified AAV helper plasmids encoding
cap serotypes 1, 6, or an 8-like isolate, and (iii) an adenovi-
rus type 5 helper plasmid (pAdhelper) expressing adeno-
virus E2A, E4 ORF6, and VA I/II RNA genes. To allow
comparisons between serotypes, a quantitative PCR-based
titration method was used to determine an encapsidated
vector genome (vg) titer utilizing a Prism 7500 Taqman
detector system (PE Applied Biosystems). [22] The primer
and fluorescent probe targeted the MCK promoter and
were as follows: MCK forward primer, 5-CCCGAGAT-
GCCTGGTTATAATT-3; MCK reverse primer, 5-GCTCAG-
GCAGCAGGTGTTG-3; and MCK probe, 5-FAM-
CCAGACATGTGGCTGCTCCCCC-TAMRA-3.
Gene Expression analysis
Tibialis anterior (TA) and gastrocnemius skeletal muscles
were collected from mdx treated and contralateral control
limbs at 4, 8, and 12 weeks post treatment. Muscles were
embedded in 7% gum tragacanth and flash frozen in iso-
pentane cooled in liquid nitrogen. Cryostat sections (12
µm) for immunostains were incubated with the N-termi-
nal Manex1a primary antibody (Developmental Studies
Hybridoma Bank), alpha-sarcoglycan (Vector, VP-A108),
or beta-sarcoglycan (Vector, VP-B206) primary antibody
at a dilution of 1:50 in blocking buffer (PBS, 10% goat
serum, 0.1% Triton x-100) for 1 hour at room tempera-
ture in a wet chamber. Sections were then washed with
PBS three times, each for 20 minutes and re-blocked. Vis-
ualization was achieved by incubation for 30 minutes at
room temperature with an Alexa 488 or Alexa 594-conju-
gated isotype-specific goat anti-mouse antibody at a 1:300
dilution (Molecular Probes). Sections were washed in PBS
3 times for 20 minutes and mounted with Vectashield
mounting medium (Vector Laboratories). Fluorescence
staining for micro-dystrophin was visualized at an excita-
tion wavelength of 488 nm for fluorescein isothiocyanate
(FITC) using a Zeiss Axioskop2 Plus Microscope and
images were captured with a Zeiss AxioCam MRC5 cam-Page 3 of 11
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staining was expressed as percent of all dystrophin posi-
tive fibers.
Western Blot Analysis
Tissue sections from wild-type C57/BL10, mdx
rAAV.micro-dystrophin treated, and mdx control mice
(10–20 µm thick) were collected into a microcentrifuge
tube and homogenized with 100 µl homogenization
buffer (125 mM Tris-HCL, 4% SDS, 4 M urea, 5% β-mer-
captoethanol, 10% glycerol, 0.001% bromophenol blue,
1 N HCL) in the presence of 1 protease inhibitor cocktail
tablet (Roche). After homogenization, the samples were
boiled for 5 min and centrifuged at 16,000 × g for 5 min-
utes. The total protein content of the supernatant was
measured using the Bio-Rad Protein Assay (Bio-Rad Labo-
ratories). Protein samples (75 µg per lane) were electro-
phoresed on a 3–8% polyacrylamide Tris-Acetate gel
(NuPAGE, Invitrogen) for 16 h at 23 V and then trans-
ferred to a PVDF membrane (Amersham Biosciences) for
1 h at 100 V at 4°C. The membrane was blocked in 5%
nonfat dry milk in TBST (100 mM Tris-HCL, pH 8.0, 167
mM NaCL, 0.1% Tween) for 1 h, and then incubated with
a 1:200 dilution of the primary monoclonal antibody
Manex1a (Developmental Studies Hybridoma Bank) and
a muscle specific actin monoclonal antibody (Vector
Labs) in TBST/5% dry milk for 1 h at room temperature in
a heat sealed bag. Anti-mouse secondary-HRP (Dako) was
used for ECL immunodetection (Amersham Biosciences).
Morphometrics
Centralized nuclei counts were performed on sections of
TA muscles stained with hematoxylin and eosin (H&E)
from 3-month-old mdx animals treated with either rAAV6
or rAAV8 micro-dystrophin. TAs from the contralateral
extremity served as controls. Five random 20× fields of 12
µm sections for each muscle were captured and the
number of fibers with central nuclei counted. Fiber diam-
eter measurements were also performed on TA muscles
from 3-month-old mdx animals treated with either rAAV6
or rAAV8 micro-dystrophin and stained with succinic dey-
hydrogenase to delineate mitochondria-enriched fibers
representing slow twitch oxidative (type 1), fast twitch
oxidative glycolytic (type 2A), and fast twitch glycolytic
(type 2B) fiber types. Controls were contralateral TA mus-
cles. Five random 20× fields of 12 µm sections for each
muscle were captured with a Zeiss AxioCam MRC5 cam-
era. For each fiber type, the smallest diameter was meas-
ured using Zeiss Axiovision LE4 software. A frequency
distribution was performed to represent the percent
number of fibers within 10 µm intervals.
Force generation and protection from eccentric 
contractions
Eight weeks post gene transfer, mice were euthanized and
the extensor digitorum longus (EDL) muscle was
removed, weighed, and bathed in oxygenated Krebs-
Henseleit solution (95% O2/5% CO2 (pH 7.4), 118 mM
NaCl, 25 mM NaHCO3, 5 mM KCl, 1 mM KH2PO4, 2.5
mM CaCl2, 1 mM MgCl2, 5 mM Glucose) at 30°C in a cir-
culating bath. One end of the muscle was tied to a force
transducer and the other to a high-speed linear servo-con-
trolled motor. Muscle length was changed at predeter-
mined values and speeds using customized software. The
muscle was mounted in the set-up at slack length with a
resting tension of 1 g for 10 minutes without electrical
stimulation. Stimulation was delivered via two parallel
platinum-iridium electrodes on either side of the muscle.
Muscles were adjusted to optimum length (L0), defined as
the length for maximal twitch and subjected to three iso-
metric tetani of 150 Hz, each for 500 ms with 1 minute
between stimulations. Following a 5 minute rest period,
muscles were subjected to a protocol of a series of 4 iso-
metric tetani with increasing frequencies of 50, 80, 120,
and 150 Hz, each for 500 ms with 1 minute between stim-
ulations. Following a 10 minute rest period, muscles were
subjected to an eccentric contraction protocol consisting
of a series of 10 isometric 700 ms tetani, at 2 minute inter-
vals, with a 10% lengthening of the muscles (0.5 fiber
length per second for duration of 200 ms) when maximal
force has developed at 500 ms. After the tetanus ended (at
t = 700 ms), the muscle was brought back to initial length
(at the same speed as the stretch), allowing for full relaxa-
tion to the initial length. For comparative purposes, all
force measurements are expressed per unit cross-sectional
area (normalized isometric force or tension: mN/mm2).
Cross-sectional area (CSA) was calculated using the fol-
lowing equation, CSA = (muscle mass in g)/[(optimal
fiber length in cm) × (muscle density in g/cm3)], where
muscle density is 1.06 g/cm3.
Statistical analyses
Data were analyzed with standard statistical methods and
expressed as means ± SEM (or as indicated). A paired t-test
or a one-way ANOVA was used to determine statistical sig-
nificance between groups. Significance level was set at p =
0.05.
Results
Construction of rAAV1, 6, and 8 vectors carrying a micro-
dystrophin cDNA
The first goal was the identification of an optimal rAAV
serotype demonstrating efficient vascular egress into
underlying muscle tissue considering scalability of viral
doses, and the use of volumes and perfusion pressures
appropriate for clinical application. Based on published
work, AAV serotypes 1, 6 and 8, emerged as leading candi-Page 4 of 11
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trophin gene under the control of a truncated MCK
promoter/enhancer (563 bp) to achieve muscle specific
gene expression, and avoid promiscuous transgene
expression in undesired cell types, helping to reduce trans-
gene-related host immune responses. The micro-dys-
trophin construct, (R4–R23/∆71–78), identical to that
described by Harper et al. [20] and later used by
Yoshimura et al. [12], contains the N-terminus, the actin-
binding domain, four spectrin repeats and hinges 1, 2 and
4, and the cysteine-rich domain (Fig. 1A). Murine micro-
dystrophin cDNA was synthesized using species specific
codon optimization. Several cis modifications were added
to achieve maximum gene expression: (1) an intron
derived from SV40 (120 bp) to augment mRNA process-
ing, stability and nuclear export [23]; (2) an small syn-
thetic polyadenylation signal to minimize construct size
and (3) inclusion of a consensus Kozak sequence
(CCACC) as a translation initiation signal. All vectors
were prepared using an adenovirus-free transient plasmid
DNA transfection protocol and were purified by a combi-
nation of iodixanol density gradient and fast protein liquid
chromatography (FPLC) ion exchange chromatography.
Vector genome titers were measured by Taqman Q-PCR as
previously described by our group. [22]
ILP delivery of rAAV6 and rAAV8 results in efficient micro-
dystrophin in the mouse hindlimb
rAAV1, 6, or 8.MCK.micro-dystrophin vector was perfused
(100 µl volume) at a dose of 1011 vg in sterile Tris buffered
saline into the femoral artery of the left hindlimb of 3–4
week old mdx mice. Details of catheter placement are pro-
vided in the methods, but certain steps deserve emphasis.
Anatomical restrictions in the mouse led to catheter place-
ment below the take off of the deep femoral artery, a
major source of blood supply to the thigh and muscle.
Prior to vector administration, and before isolating blood
flow to the extremity, the arterial catheter was flushed
(pre-flush) with 100 µl sterile normal saline. Subse-
quently a 6-0 braided silk ligature was tightened to pre-
vent all blood flow to the extremity (isolated limb
perfusion-ILP) proximal to the site of catheter introduc-
tion. Immediately after ligature tightening, vector was
slowly administered (over 60 to 80 seconds) to minimize
capillary rupture. Following a ten minute dwell time, a
100 ul saline post-flush was performed immediately
before removing the tourniquet. The tibialis anterior (TA),
extensor digitorum longus (EDL), gastrocnemius, and
soleus were harvested at 1, 2, and 3 months post transfer.
Micro-dystrophin gene expression was quantified by
immuno-staining of muscle cross sections using a mono-
clonal antibody (Manex-1a) against the N-terminus of
micro-dystrophin. Widespread micro-dystrophin expres-
sion was observed in the TA and EDL muscles of mice
receiving rAAV6 and rAAV8 at all three time points (Fig.
1B). Fiber counts revealed that rAAV8.micro-dystrophin
cohorts exhibited 94.5 ± 0.9% (1 month), 91.3 ± 3.1% (2
months), and 89.6 ± 1.6% (3 months) transduction; and
rAAV6.micro-dystrophin treated animals demonstrated
87.7 ± 6.8% (1 month), 78.9 ± 7.4% (2 months), and
81.2 ± 6.2% (3 months) transduction (Fig. 2). The gas-
trocnemius and soleus demonstrated lower levels of
expression with mean transduction efficiencies over all 3
(A) Schematic of murine micro-dystrophin constructFigure 1
(A) Schematic of murine micro-dystrophin construct. A trun-
cated MCK promoter/enhancer (563 bp) is used to drive 
muscle specific gene expression. Also labeled is a chimeric 
SV40 intron (97 bp) and synthetic polyadenylation site (53 
bp). The 3,590 bp murine micro-dystrophin construction is 
depicted in detail. ABD is the complete actin binding domain, 
hinges 1, 2 and 4 are shown (green boxes), as are the flanking 
spectrin rod domains (SR blue boxes). The cysteine-rich dys-
troglycan binding domain is denoted by an orange box. AAV2 
ITR are shown as arrowheads. (B) Immunofluorescence 
detection of micro-dystrophin expression in mdx mouse TA 
muscle. rAAV1, 6, or 8.micro-dystrophin (1011 vg) was deliv-
ered by intramuscular injection (IM Control) or ILP through 
the femoral artery of 3–4 week old mdx mice. Representative 
TA muscle sections (12 um) are shown from 4 week post-
injected animals (8 and 12 weeks looked similar). Sections 
were immuno-stained with the N-terminal dystrophin anti-
body Manex1a. Scale Bar, 50 µm.Page 5 of 11
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and 17.6 ± 1.4% for rAAV6.micro-dystrophin. This is
likely attributed to catheter placement and the anatomy of
the vasculature of the mouse hindlimb. In the mouse, the
femoral artery bifurcates at the level of the knee with one
arterial branch supplying the TA and EDL and two smaller
branches which turn posteriorly and perfuse the two
heads of the gastrocnemius and soleus. The femoral cath-
eter was placed just above the knee with delivery of vector
directed toward the more accessible arterial branch to the
TA, complicit with a low volume/pressure system. In con-
trast to rAAV8 and rAAV6, vascular delivery of micro-dys-
trophin by rAAV1 did not efficiently transduce the
muscles of the lower limb with 0.9 ± 0.3% (1 month), 2.1
± 0.8% (2 months), and 2.1 ± 0.7% (3 months) transduc-
tion (Fig. 2). This could not be attributed to the biological
activity of the vector preparation since direct muscle injec-
tion into the TA, performed in parallel with the vascular
injections, resulted in robust and equivalent gene expres-
sion for all three serotypes at 1 month post injection; 94.0
± 1.2% (rAAV1), 95.5 ± 0.7% (rAAV6), and 95.1 ± 0.6%
(rAAV8) (Fig. 1B). Our inability to observe vascular deliv-
ery using this rAAV1 serotype is in contrast to previous
studies using arterial perfusion in mice. [18,24,25] Differ-
ences in dose, injection volume, and pressure best explain
the dissimilar results (see discussion). Consistent with our
immunofluorescence data, western blot analysis revealed
the presence of the expected 138 kDa micro-dystrophin
protein rAAV6 and 8 cohorts (data not shown).
Micro-dystrophin expression levels result in reduced mdx 
pathology
The major wave of necrosis and regeneration in the mdx
mouse occurs at approximately 3 to 4 weeks of age, coin-
cident with our vector administration. Maximum gene
expression from single-stranded rAAV vectors does not
occur until about 4 weeks post gene transfer. Thus, the
effects on mdx pathology may be modest. Quantitation of
central nuclei was determined in the TA muscles treated
with rAAV6 or rAAV8 micro-dystrophin and compared
with controls. Central nucleation was reduced by only
25% (rAAV8 – 65.3 ± 3.3%, rAAV6 – 64.05 ± 3.4%, vs
mdx – 86.16 ± 0.9%; P < 0.0001; Fig. 3E), reflecting pro-
tection against recurring cycles of regeneration and degen-
eration only between the time of gene expression and
necropsy (2 months post gene transfer). Detailed mor-
phometric analysis of fiber diameter revealed that both
rAAV6 and rAAV8 treated groups exhibited an increase in
myofiber diameter compared to controls. Cross sections
from treated and control muscles were stained to deline-
ate slow twitch (type 1), fast twitch oxidative glycolytic
(type 2A) and fast twitch glycolytic (type 2B) fiber types,
with slow twitch fibers demonstrating the largest increase
(Fig. 3F). Significant differences in mean fiber diameter
(µm) were seen in rAAV8.microdystrophin treated ani-
mals compared to mdx for all three fiber types [type 1–
39.2 ± 0.4 (rAAV8) vs 30.2 µm (mdx); type 2A – 48.2 ± 0.7
vs 38.9 ± 0.5 µm; type 2B – 52.4 ± 0.8 vs 47.1 ± 0.6 µm
where P < 0.0001], while AAV6.microdystrophin treated
animals exhibited significant differences for type 1 (33.2
± 0.3 µm; P < 0.0001) and type 2A (40.8 ± 0.5 µm; P <
0.01) fibers. The largest differences for both rAAV8 and
rAAV6.microdystrophin treated animals were demon-
strated in type 1 (slow twitch) fibers with a 23% and 10%
increase in fiber diameter, respectively. These differences
are further demonstrated in Figure 3 where frequency dis-
tribution of fiber diameters stratified by fiber type demon-
strates an overall shift toward larger diameter for both
rAAV8 and rAAV6.micro-dystrophin cohorts. ANOVA was
performed on all data sets and demonstrated significance
for both groups compared to mdx controls (P < 0.0001).
Lastly, consistent with biological activity, micro-dys-
trophin levels were sufficient to restore proper localiza-
tion of dystrophin-associated proteins (DAP) proteins α-
sarcoglycan, and β-sarcoglycan in rAAV6 and rAAV8
cohorts (Fig. 4).
rAAV mediated micro-dystrophin expression via ILP results 
in significant force generation improvement in mdx 
animals
To test whether widespread micro-dystrophin expression
led to improvement at a functional level, the force gener-
ation properties of the EDL muscle from mdx mice treated
with rAAV.micro-dystrophin were compared with
untreated mdx and wild-type C57/B10 controls. Eight
weeks post transfer, animals were euthanized and the EDL
was dissected for in vitro force measurements. rAAV8- and
rAAV6-treated muscles exhibited a 50% improvement in
maximum isometric force compared to mdx when nor-
Quantification of micro-dystrophin protein expressionFigure 2
Quantification of micro-dystrophin protein expression. 
Micro-dystrophin distribution in muscle sections (4, 8, 12) 
weeks was quantified by visual fiber counts (images from 4 
random fields) of the number of positive fibers/total fibers 
and represented as a percent mean ± SEM (n = 4–8 per 
group).Page 6 of 11
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(rAAV8.micro-dystrophin 146.5 ± 7.6 mN/mm2,
rAAV6.micro-dystrophin 142.2 ± 14.8 mN/mm2 vs. mdx-
untreated 109.5 ± 5.1 mN/mm2; P < 0.05) (Fig. 5A). The
increase in developed force did not completely reach the
level of age-matched C57BL/10 wild-type controls (198.3
± 11.9 mN/mm2; P < 0.05) (Fig. 5A). After assessment of
specific force, the muscles were subjected to mechanical
damage by repetitive eccentric contractions. Micro-dys-
trophin expression by rAAV8 and rAAV6 showed protec-
tion against eccentric contraction injury. Analyzing the
force generation after the first lengthening contraction by
comparing the ratio of the second versus the first contrac-
tion revealed that mdx-untreated muscles decayed 0.54 ±
0.02 versus rAAV8 at 0.70 ± 0.08, and rAAV6 at 0.61 ±
0.04. The treated muscles were significantly more resistant
to contraction-induced injury compared to untreated mdx
(p < 0.05); neither treated group differed significantly
from WT controls, which decay by 0.69 ± 0.08 (Fig. 5B,
5C). Due to the robust eccentric injury protocol, even in
WT muscles, from the third contraction on no differences
were observed between any groups. Combined, these data
demonstrate that micro-dystrophin delivered by either
rAAV6 or rAAV8 through the vasculature leads to signifi-
cant improvement in isometric developed force and sig-
nificantly attenuates eccentric contraction injury.
ILP using rAAV8 in cynamologous macaques results in 
widespread gene expression in the lower limb
The translational goal is to apply pre-clinical findings to a
clinical paradigm. Non-human primates (NHP) offer a
testing ground to extend vascular delivery to a model with
anatomic parallels to humans, as well as to establish
approximate dosing ranges similar to a young child. The
dose administered to macaques was proportional (based
on animal weight) to that given to the mice (5 × 1012 vg/
kg in mouse and 2 × 1012 vg/kg in the NHP). The left hind-
limb of two cynamologous macaques (4–5 kg animals)
Micro-dystrophin expression levels result in reduced mdx pathologyFigure 3
Micro-dystrophin expression levels result in reduced mdx pathology. Hematoxylin and Eosin (H&E) analysis revealed a reduc-
tion in centralized nuclei, a hallmark of DMD pathology. (A, C) H&E staining of rAAV6 and rAAV8 micro-dystrophin muscle 
sections, respectively (8 week time point). (B,D) Micro-dystrophin immunofluorescence detection in serial sections of rAAV6 
and rAAV8 cohorts, respectively. Scale Bar, 25 µm. (E) Micro-dystrophin expression results in a 25% decrease in centralized 
nuclei. (F) Frequency distribution demonstrating micro-dystrophin expression results in a significant increase in type I, IIa, and 
IIb fiber diameter for rAAV6 and rAAV8.micro-dystrophin injected mdx mice compared to mdx controls. (n = 5–6 per group) 
(p < 0.0001 ANOVA analysis).Page 7 of 11
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rAAV8.CMV.eGFP in 2 ml PBS using a custom made,
fluoroscopy guided catheter that was advanced to the arte-
rial bifurcation at the level of the knee. The procedure mir-
rored the mouse studies with a pre-flush (2 ml) prior to
obstructing flow, a 10 minute dwell time and delivery of
a post-flush (2 ml) immediately before removing the tour-
niquet (although, the femoral vein was not catheterized
for this experiment). Three weeks post transfer, the ani-
mals were euthanized and the lower limb muscles includ-
ing the TA, EDL, gastrocnemius and soleus were dissected
to compare with mdx studies. GFP was visualized by direct
fluorescence and demonstrated widespread gene expres-
sion in all muscles analyzed [medial gastrocnemius – 63.8
± 4.9%, lateral gastrocnemius – 66.0 ± 4.5%, EDL – 80.2
± 3.1%, soleus – 86.4 ± 1.9%, TA – 72.2 ± 4.0% (Fig. 6).
Means were obtained by counting 4 fields from 4–6 mus-
cle blocks for each muscle spanning proximal, central,
and distal regions for a total of 16–24 – 20× fields (field =
0.349 mm2) per muscle. These data demonstrate that
rAAV8 is efficient at gaining access to the underlying mus-
culature in the primate host and appears to be an ideal
serotype for delivery to multiple muscle groups via the
vasculature using a low volume, low pressure, and low
dose experimental paradigm.
Discussion
Successful gene therapy for DMD will require widespread
muscle transduction using a replacement gene, presuma-
bly a mini- or micro-dystrophin or a surrogate gene.
[20,26] Success in the mdx mouse with tail vein delivery
is notable, [9,10] but key issues for translation to clinical
trials have been wanting. In this study we focused on a
vascular delivery system that can be adapted for a clinical
protocol in an effort to achieve a clinically meaningful
outcome, providing safe passage for the virus, and using a
dose within the manufacturing constraints for rAAV vec-
tors. We reasoned that a regional vascular delivery
approach to the lower limbs through the femoral artery
could potentially meet these expectations. This is similar
in concept to local versus systemic gene transfer to the
liver as demonstrated by Hodges et al. [27]
The first step in this process was to identify the appropri-
ate AAV serotype that would efficiently cross the vascular
barrier using a conditional paradigm of low pressure and
low volume. Based on prior studies, there are advocates
for AAV6 and AAV8; however, viral loads, vascular trans-
port enhancing agents, and ages of animals [10,15] pre-
clude direct comparisons between these serotypes in the
published literature. AAV1 also has demonstrated activity
Components of the dystrophin-associated protein complex are restored in mdx mice treated with rAAVFigure 4
Components of the dystrophin-associated protein complex are restored in mdx mice treated with rAAV.micro-dystrophin 
gene transfer. mdx mice treated with rAAV8.micro-dystrophin delivered by ILP (8 week time point) were serial sectioned and 
stained with manex1a antibody for dystrophin, α-sarcoglycan, β-sarcoglycan, and H &E. Muscle fibers transduced with micro-
dystrophin also exhibited restoration of expression of α-sarcoglycan and β-sarcoglycan (no staining in untreated mdx mice – 
bottom row). Muscle fibers from serial sections exhibited identical expression localization for each protein (arrow).Page 8 of 11
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again conditions for delivery cannot be directly compared
with AAV6 and AAV8. For clinical trials, we anticipate a
regional vascular delivery approach. The femoral artery
supplying major muscle groups in the lower extremity
represents a potential first target necessitating comparing
AAV serotypes (AAV1, AAV6, and AAV8), carrying the
same transgene (a modified micro-dystrophin), under
control of the same promoter (MCK), using identical
delivery conditions appropriate for a clinical setting. The
results were unambiguous. AAV6 and AAV8 performed
equally well for regional vascular delivery to the lower
limb, which was strikingly different from AAV1. We found
widespread micro-dystrophin expression in the TA and
EDL at 1, 2, and 3 months post gene transfer (Fig. 1B),
with insignificant differences in quantitation of trans-
duced myofibers (rAAV8 > 90% and rAAV6 > 80%). These
transduction efficiencies through a vascular route of deliv-
ery demonstrated a significant increase in isometric force
generation and partial protection from contraction-
induced injury compared to mdx (Fig. 5).
The transduction efficiency for rAAV1 was dramatically
lower (<3%). We attribute the differences between our
results with AAV1 and those of prior studies [18,25] most
likely related to the volume of perfusate [1 ml vs 100 µl
(current study) per 20 g body weight] and the rate of
administration [delivered over 10–39 seconds vs 60–80
Isolated limb perfusion of rAAV8.CMV.eGFP in cynomolo-gous macaques (4–5 kg) resulted in wid spread ge e expres-si n in lower limb musclesFigure 6
Isolated limb perfusion of rAAV8.CMV.eGFP in cynomolo-
gous macaques (4–5 kg) resulted in widespread gene expres-
sion in lower limb muscles. Using a custom (PE 50 Tubing) 
made catheter and the aid of a 0.018 m guide wire and fluor-
oscopy, 2 × 1012 vg/kg (2 ml volume) was administered via 
the femoral artery. A tourniquet occluded flow during a 10 
minute dwell time to allow vector to bind. Three weeks post 
transfer, robust transduction was observed in muscles per-
fused by peroneal vessels (TA and EDL) and tibial vessels 
(Med and Lat. Gas. – medial and lateral gastrocnemius and 
soleus) (n = 2). Scale Bar, 100 µm.
rAAV.micro-dystrophin gene transfer improves force gener-ation easurements s gnifican lyFigure 5
rAAV.micro-dystrophin gene transfer improves force gener-
ation measurements significantly. (A) rAAV8.micro-dys-
trophin and rAAV6.micro-dystrophin treated mdx extensor 
digitorum longus (EDL) muscles (8 week time point) demon-
strated significant maximum specific force improvement 
(mN/mm2) over mdx-untreated muscles (p < 0.05) but did 
not reach levels of age-matched C57BL/10 wild type (WT) 
controls (P < 0.05). Values are presented as the means ± 
SEM, (B) EDL muscles were subjected to 10 cycles of isomet-
ric stimulation at 150 Hz with a 10% lengthening to induce 
damage during the last 100 ms of each contraction. Force val-
ues are represented as fractions of the first contraction. 
rAAV8.micro-dystrophin and rAAV6.micro-dystrophin 
treated EDL muscles exhibited significant protection from 
damage compared to mdx-untreated during the first two 
cycles (p < 0.05), while thereafter all 4 groups showed such 
robust injury that differences could no longer be determined. 
There was no significant difference between rAAV8- or 
rAAV6-treated and WT. (C) The ratio of force (ECC2/
ECC1) after one lengthening contraction of rAAV-treated 
versus the initial contraction of WT is not different, but is 
significantly improved compared to mdx-untreated (n = 6–8 
per group; P < 0.05).Page 9 of 11
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transfer, Gonin et al. demonstrated capillary rupture
within the endomysium that more than likely accounts
for the high rate of gene expression. They also observed
edema of the extremity. Although we did not directly
examine the capillary bed in our preparations, we suggest
that vascular integrity was maintained based on the fol-
lowing: 1) there was no extremity swelling in our mice; 2)
AAV1, AAV6, and AAV8 demonstrated equal transduction
efficiencies following intramuscular injections with >94%
gene expression, yet impressive differences were seen fol-
lowing vascular gene transfer suggesting a distinction
based on vascular endothelial transport, or 3) preferential
inhibitory binding within the vasculature by rAAV1.
In the course of testing the serotypes for delivery of micro-
dystrophin it was our intent to develop a gene transfer
approach that could potentially be adapted to the clinic.
In mouse we used isolated limb perfusion, a pre-flush of
saline prior to gene delivery, a dwell time with all circula-
tion occluded, and a post flush with an open venous sys-
tem to rid the extremity of as much vector as possible. We
believe that a pre-flush could have particular significance
in a clinical trial where pre-existing antibody is a major
threat to organ transduction. [27,28] Even in the absence
of pre-existing immunity, delivery of the virus in an envi-
ronment free of serum and particulate material (comple-
ment proteins, platelets, erythrocytes, leucocytes), with its
potential viral-binding capacity, provides a clearer path to
muscle transduction and an added safety factor because of
reduced risk for carrying virus to remote sites. In addition,
a prolonged dwell time with occluded circulation in the
presence of platelets and other clotting factors could lead
to a blood clot in the extremity with potential serious con-
sequences.
In the mouse, attention to the factors outlined resulted in
80% to 90% muscle transduction using rAAV6 and rAAV8
carrying micro-dystrophin. In an attempt to avoid putting
too much emphasis on success in the mouse, we extended
our studies to the non-human primate employing condi-
tions that would closely simulate a clinical regional vascu-
lar delivery model. Thus, in the monkey we directly tested
rAAV8 delivery of eGFP through an isolated femoral artery
using conditions that would be applicable for a clinical
trial (low pressure, low volume, and without pharmaco-
logic agents). We used viral doses appropriate for clinical
production runs (2 × 1012 vg/kg), and at the same time
achieved levels of muscle gene expression in lower limbs
predictive of a therapeutic benefit. [29]
Our study fulfills stringent criteria for gene delivery with
implications for clinical application using an approach
and AAV serotype that will potentially accelerate efforts to
produce life-altering results in children with DMD, with
applicability to other muscular dystrophies. Additional
work in the monkey is required, especially using a cassette
more analogous to one that will be used in practice. Stud-
ies in the non-human primate do provide a number of
advantages including a >90% genomic sequence homol-
ogy to humans, accounting for wide application to vac-
cine research and organ transplantation. The monkey is
also well thought of for translational research for gene
therapy owing to its high rate of natural infection by AAV
similar to humans. [30] This is particularly relevant to
studies of AAV8 gene transfer where translational para-
digms, using monkeys with and without pre-existing
immunity, permit study of specific immunosuppressive
regimens. To successfully transfer rAAV to a canine dystro-
phy model, Wang et al. [19] were required to use anti-thy-
mocyte globulin, cyclosporine and mycophenolate
mofetil. The work presented here paves the way for studies
of gene expression in a primate host under conditions that
will be appropriate for the clinic using regional vascular
delivery. Specific muscle groups in the limbs can be per-
fused and critical sites, like the diaphragm and heart, can
be targeted. Studies in the monkey will also permit further
sophistication in gene delivery, using fluoroscopy-guided
balloon catheters for precise delivery of vector to isolated
vascular regions with the advantage of subsequent
removal of unbound virus reducing potential for spread
to remote sites.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
LRK generated the rAAV.MCK.micro-dystrophin construct
and the corresponding rAAV1, rAAV6, and rAAV8 vectors,
performed intramuscular injections, harvested muscle tis-
sue, and performed all immunohistochemistry and mor-
phometric analysis. PMLJ conducted all physiology
experiments. CLM, BDC, LRK, and LGC conducted the
isolated limb perfusion experiments in mice and non-
human primates. KRC oversaw rAAV vector production.
LRK, LGC, KRC, and JRM conceived the study, partici-
pated in its design and coordination, and drafted the
manuscript. All authors read and approved the final man-
uscript.
Acknowledgements
We thank the CCRI Viral Vector Core Laboratory for vector support. The 
Manex1a antibody developed by Glen Morris, Centre for Inherited Neu-
romuscular Disease, RJAH Orthopaedic Hospital, UK, was obtained from 
the Developmental Studies Hybridoma Bank developed under the auspices 
of NICHD and maintained by the University of Iowa, Department of Bio-
logical Sciences, Iowa City, IA 52242. Research supported by the Children's 
Hospital Foundation (JRM); National Institutes of Health Wellstone Muscu-
lar Dystrophy Cooperative Research Center (AR03001 to JRM); Muscular Page 10 of 11
(page number not for citation purposes)
Journal of Translational Medicine 2007, 5:45 http://www.translational-medicine.com/content/5/1/45Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Dystrophy Association (JRM); Ruth L. Kirschstein NRSA postdoctoral fel-
lowship (1F32AR055008 to LRK).
References
1. Emery AE: Population frequencies of inherited neuromuscular
diseases--a world survey.  Neuromuscul Disord 1991, 1(1):19-29.
2. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller
JP, King W, Signore L, Pandya S, Florence J, et al.: Randomized, dou-
ble-blind six-month trial of prednisone in Duchenne's muscu-
lar dystrophy.  N Engl J Med 1989, 320(24):1592-1597.
3. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ,
van Deutekom JC: Exploring the frontiers of therapeutic exon
skipping for Duchenne muscular dystrophy by double target-
ing within one or multiple exons.  Mol Ther 2006, 14(3):401-407.
4. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD: Anti-
sense oligonucleotide-induced exon skipping restores dys-
trophin expression in vitro in a canine model of DMD.  Gene
Ther 2006, 13(19):1373-1381.
5. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL:
Aminoglycoside antibiotics restore dystrophin function to
skeletal muscles of mdx mice.  J Clin Invest 1999, 104(4):375-381.
6. Hamed SA: Drug evaluation: PTC-124--a potential treatment
of cystic fibrosis and Duchenne muscular dystrophy.  IDrugs
2006, 9(11):783-789.
7. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies
K: Expression of full-length utrophin prevents muscular dys-
trophy in mdx mice.  Nat Med 1998, 4(12):1441-1444.
8. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA,
Ahima RS, Khurana TS: Functional improvement of dystrophic
muscle by myostatin blockade.  Nature 2002,
420(6914):418-421.
9. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse
L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS:
rAAV6-microdystrophin preserves muscle function and
extends lifespan in severely dystrophic mice.  Nat Med 2006,
12(7):787-789.
10. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L,
Miller DG, Russell DW, Chamberlain JS: Systemic delivery of
genes to striated muscles using adeno-associated viral vec-
tors.  Nat Med 2004, 10(8):828-834.
11. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D:
Adeno-associated virus-mediated microdystrophin expres-
sion protects young mdx muscle from contraction-induced
injury.  Mol Ther 2005, 11(2):245-256.
12. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miya-
goe-Suzuki Y, Takeda S: AAV vector-mediated microdystrophin
expression in a relatively small percentage of mdx myofibers
improved the mdx phenotype.  Mol Ther 2004, 10(5):821-828.
13. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Inno-
cenzi A, Mognol P, Thibaud JL, Galvez BG, Barthelemy I, Perani L,
Mantero S, Guttinger M, Pansarasa O, Rinaldi C, Cusella De Angelis
MG, Torrente Y, Bordignon C, Bottinelli R, Cossu G: Mesoangiob-
last stem cells ameliorate muscle function in dystrophic
dogs.  Nature 2006, 444(7119):574-579.
14. Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D, Davies
KE, Cornelio F, Pozza O, Karpati G, Gilbert R, Mora M: Dystrophic
phenotype of canine X-linked muscular dystrophy is miti-
gated by adenovirus-mediated utrophin gene transfer.  Gene
Ther 2003, 10(9):750-757.
15. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao
X: Adeno-associated virus serotype 8 efficiently delivers
genes to muscle and heart.  Nat Biotechnol 2005, 23(3):321-328.
16. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM:
Gene therapy vectors based on adeno-associated virus type
1.  J Virol 1999, 73(5):3994-4003.
17. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR:
Genetic fate of recombinant adeno-associated virus vector
genomes in muscle.  J Virol 2003, 77(6):3495-3504.
18. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L,
Danos O: Rescue of dystrophic muscle through U7 snRNA-
mediated exon skipping.  Science 2004, 306(5702):1796-1799.
19. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamber-
lain JS, Tapscott SJ, Storb R: Sustained AAV-mediated dys-
trophin expression in a canine model of Duchenne muscular
dystrophy with a brief course of immunosuppression.  Mol
Ther 2007, 15(6):1160-1166.
20. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW,
Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Cham-
berlain JS: Modular flexibility of dystrophin: implications for
gene therapy of Duchenne muscular dystrophy.  Nat Med
2002, 8(3):253-261.
21. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski
RJ: Cross-packaging of a single adeno-associated virus (AAV)
type 2 vector genome into multiple AAV serotypes enables
transduction with broad specificity.  J Virol 2002, 76(2):791-801.
22. Clark KR, Liu X, McGrath JP, Johnson PR: Highly purified recom-
binant adeno-associated virus vectors are biologically active
and free of detectable helper and wild-type viruses.  Hum Gene
Ther 1999, 10(6):1031-1039.
23. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL:
Heterologous introns can enhance expression of transgenes
in mice.  Proc Natl Acad Sci U S A 1991, 88(2):478-482.
24. Fougerousse F, Bartoli M, Poupiot J, Arandel L, Durand M, Guerchet
N, Gicquel E, Danos O, Richard I: Phenotypic Correction of
alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a
Muscle-specific Serotype 1 rAAV Vector.  Mol Ther 2007,
15(1):53-61.
25. Gonin P, Arandel L, Van Wittenberghe L, Marais T, Perez N, Danos
O: Femoral intra-arterial injection: a tool to deliver and
assess recombinant AAV constructs in rodents whole hind
limb.  J Gene Med 2005, 7(6):782-791.
26. Wang B, Li J, Xiao X: Adeno-associated virus vector carrying
human minidystrophin genes effectively ameliorates muscu-
lar dystrophy in mdx mouse model.  Proc Natl Acad Sci U S A
2000, 97(25):13714-13719.
27. Hodges BL, Taylor KM, Chu Q, Scull SE, Serriello RG, Anderson SC,
Wang F, Scheule RK: Local delivery of a viral vector mitigates
neutralization by antiviral antibodies and results in efficient
transduction of rabbit liver.  Mol Ther 2005, 12(6):1043-1051.
28. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo
MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A,
Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Les-
sard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi
F, Couto L, Ertl HC, High KA, Kay MA: Successful transduction of
liver in hemophilia by AAV-Factor IX and limitations
imposed by the host immune response.  Nat Med 2006,
12(3):342-347.
29. Foster K, Foster H, Dickson JG: Gene therapy progress and
prospects: Duchenne muscular dystrophy.  Gene Ther 2006,
13(24):1677-1685.
30. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J:
Immune responses to adenovirus and adeno-associated virus
in humans.  Gene Ther 1999, 6(9):1574-1583.Page 11 of 11
(page number not for citation purposes)
